←
Nikos Vasilakis933 posts
Nikos Vasilakis avatar

Nikos Vasilakis

@Vasilakis_Lab

Our focus is to understand the mechanisms that allow zoonotic, sylvatic arthropod-borne viruses to jump species boundaries and cause disease. Shared lab account

◷ Joined October 2019▧ 319 Photos and videos
UTMB Provost's Office avatar
⟳ Nikos Vasilakis retweeted
UTMB Provost's Office@UTMBProvost·Oct 29

Achieving the rank of professor is a crowning achievement of a career in academia. In FY26, UTMB appointed or promoted 17 new professors, and we had the pleasure of celebrating with many of them at last night's Professors' Dinner. Congratulations to all our new professors!

Post attachmentPost attachmentPost attachmentPost attachment
NIH avatar
⟳ Nikos Vasilakis retweeted
NIH@NIH·Sep 29

NIAID has awarded $17.9M to re-establish the Centers for Research in Emerging Infectious Diseases Network (CREID) program with the highest possible standards for biosafety and biosecurity to protect the public. Learn more:

UTMB Provost's Office avatar
⟳ Nikos Vasilakis retweeted
UTMB Provost's Office@UTMBProvost·Sep 1

Dr. Scott Weaver’s distinguished career has helped shape the modern understanding of emerging infectious diseases while establishing UTMB as a global leader in this realm. He will receive the UTMB Lifetime Achievement in Research Award on 9/10! Info: utmb.us/g9v

Post attachment
Jochen Reiser MD PhD avatar
⟳ Nikos Vasilakis retweeted
Jochen Reiser MD PhD@JochenReiser·Aug 6

Today marks a defining moment for @UTMBHealth and the future of cardiovascular medicine. The Sealy & Smith Foundation has committed $180 million to advance the Sealy Heart & Vascular Institute. This is the largest philanthropic gift in UTMB history and among the largest ever made to a cardiovascular institute at an academic medical center in the United States. 🙏 Let’s get to work and save lives. @docHJ @utsystem

Mauricio Nogueira’s lab @Famerp avatar
⟳ Nikos Vasilakis retweeted
Mauricio Nogueira’s lab @Famerp@Virology_FAMERP·Apr 20

Conducting real-time epidemiological research during a pandemic demands adaptability. In the AVISA study, we faced recruitment challenges, vaccination shifts, and logistical complexity. Progress relied on flexibility and coordination. resilient research requires rapid adaptation.

Post attachment
Jochen Reiser MD PhD avatar
⟳ Nikos Vasilakis retweeted
Jochen Reiser MD PhD@JochenReiser·Apr 13

In a disruptive environment, delay is the highest-risk strategy. Don’t wait for full clarity. Another mistake is treating AI, workforce, and strategy as separate conversations. They are one and the same transformation.

Post attachmentPost attachment
UTMB Provost's Office avatar
⟳ Nikos Vasilakis retweeted
UTMB Provost's Office@UTMBProvost·Apr 3

Congratulations to Dr. Shannan L. Rossi on being named the inaugural Associate Dean of Strategic Initiatives, @UTMBGSBS! We are grateful for her leadership as she helps advance the school’s strategic priorities and strengthen the impact of its academic and research programs.

Post attachment
Mauricio Nogueira’s lab @Famerp avatar
⟳ Nikos Vasilakis retweeted
Mauricio Nogueira’s lab @Famerp@Virology_FAMERP·Mar 11

Our new study presents an integrated pipeline for rapid epitope-based pan-alphavirus vaccine design, combining immunoinformatics, structural modeling, and experimental validation to identify broadly immunogenic candidates. Congratulations to Alice and the entire team @afversiani

Post attachment
Mauricio Nogueira’s lab @Famerp avatar
⟳ Nikos Vasilakis retweeted
Mauricio Nogueira’s lab @Famerp@Virology_FAMERP·Mar 4

We report in Nature Medicine that the single-dose Butantan dengue vaccine showed 65% efficacy against symptomatic dengue and 80.5% protection against severe disease over 5 years, with a favorable safety profile in participants aged 2–59 in Brazil.

Post attachmentPost attachment
Nikos Vasilakis avatar
Nikos Vasilakis@Vasilakis_Lab·Feb 6

Αn important study long overdue!

Maternal dengue antibodies can have two effects in infants: early protection, followed by increased risk of severe disease between 5–12 months (antibody-dependent enhancement). In Brazil dengue rose sharply from 2000–2024, with peaks of severe risk at birth and around 7–8 months.

Post attachment